Innate Pharma S.A.
IPHA
$1.36
-$0.06-4.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -77.08% | -76.37% | -75.77% | -75.93% | -75.67% |
| Total Other Revenue | -13.45% | -20.32% | -25.33% | -25.07% | -22.99% |
| Total Revenue | -53.36% | -59.25% | -62.43% | -65.98% | -67.34% |
| Cost of Revenue | -12.16% | -15.88% | -18.59% | -13.87% | -7.18% |
| Gross Profit | -13.86% | -29.15% | -56.06% | -336.32% | -668.29% |
| SG&A Expenses | 2.73% | 4.12% | 6.90% | 5.94% | 7.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.06% | -10.54% | -11.99% | -8.88% | -3.48% |
| Operating Income | -9.60% | -18.49% | -32.19% | -97.57% | -306.86% |
| Income Before Tax | -4.29% | -16.39% | -36.03% | -127.42% | -552.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.29% | -16.39% | -36.03% | -127.42% | -552.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.29% | -16.39% | -36.03% | -127.42% | -552.82% |
| EBIT | -9.60% | -18.49% | -32.19% | -97.57% | -306.86% |
| EBITDA | -11.05% | -22.65% | -37.33% | -124.34% | -552.94% |
| EPS Basic | 6.03% | -8.35% | -31.18% | -123.17% | -549.90% |
| Normalized Basic EPS | 6.03% | -8.31% | -31.13% | -123.08% | -549.92% |
| EPS Diluted | 5.87% | -8.44% | -31.08% | -122.24% | -542.55% |
| Normalized Diluted EPS | 6.03% | -8.31% | -31.13% | -122.44% | -541.84% |
| Average Basic Shares Outstanding | 10.54% | 7.35% | 4.16% | 2.45% | 0.74% |
| Average Diluted Shares Outstanding | 10.54% | 7.35% | 4.16% | 0.71% | -2.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |